DASL-HICAP

1. 00:06
   ESMO 2026 现场信号

   DASL-HiCaP at #ESMO2026:

1. 22:39
   ESMO 2026 现场信号

   Tamim Niazi, MDCM, @mcgillu on DASL-HiCaP at #ESMO26: adding darolutamide to ADT and radiation cut the risk of metastasis or death by 58% in very high-risk localized prostate cance
2. 21:40
   中文产业新闻

   DASL-HiCaP III期中期分析：达罗他胺联合放疗和ADT将高危局限期前列腺癌转移或死亡风险降低58%

   2026 ESMO公布DASL-HiCaP随机Ⅲ期中期分析，达罗他胺联合放疗和ADT将高危局限期前列腺癌患者转移或死亡风险降低58%。该研究（NCT04136353，ANZUP1801）纳入1106例患者，中位随访3.8年时两组4年MFS-CI率为95%对88%（HR=0.42，95% CI 0.27–0.66，p=0.0001）。

3. 09:38
   ESMO 2026 现场信号

   DASL-HiCap trial #ESMO26 @myESMO @Silke_Gillessen @ANZUPtrials @APCCC_Lugano @oncodaily @OncoAlert
4. 07:51
   ESMO 2026 现场信号

   🔬 #ESMO26 | La Dra. @rebecaLozMe, portavoz de @_SEOM, analiza DASL-HiCaP (LBA4), presentado en la Sesión Presidencial del Congreso de @myESMO 2026.
5. 04:57
   ESMO 2026 现场信号

   Positive DASL-HiCaP results presented at #ESMO26 @niazi_Dr7
6. 00:12
   ESMO 2026 现场信号

   🎥 #OAOnTheGo | #ESMO26 🇪🇸 in Portuguese for our 🇧🇷 🇵🇹 Colleagues
7. 00:00
   ESMO 2026 现场信号

   🔴 Just presented at #ESMO2026: DASL-HiCaP

1. 23:15
   ESMO 2026 现场信号

   Who Benefits from Treatment Intensification in High-Risk Localized or Relapsed Prostate Cancer? A Discussion of DASL-HiCaP. Presented by @Silke_Gillessen. #ESMO26 written coverage
2. 23:00
   ESMO 2026 现场信号

   DASL-HiCaP: Darolutamide + ADT and Radiation Therapy for Very High-Risk Localized Prostate Cancer, Phase 3 Interim Analysis. Presented by @niazi_Dr7. #ESMO26 written coverage by @z
3. 14:06
   ESMO 2026 现场信号

   The #OncoAlertTopTweet 🚨 #ESMO26 DAY 2
4. 10:51
   ESMO 2026 现场信号

   #ESMO2026
5. 10:10
   ESMO 2026 现场信号

   DASL-HiCaP — What's in a name? 🧠
6. 07:03
   ESMO 2026 现场信号

   🚨📣📣 #ESMO26 presidential: Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️ in MFS (HR
7. 05:38
   ESMO 2026 现场信号

   #ESMO26 @niazi_Dr7 DASL-HiCaP (ANZUP1801)
8. 05:04
   ESMO 2026 现场信号

   DASL-HiCaP: primary MFS endpoint met.
9. 03:58
   ESMO 2026 现场信号

   #ESMO26 DASL-HiCaP Presidential Discussant -- @Silke_Gillessen
10. 03:11
    ESMO 2026 现场信号

    #ScienceLink #Madrid2026 #ESMO26 #DASLHiCaP #darolutamida
11. 01:59
    ESMO 2026 现场信号

    🎯 4-year MFS of 95% vs 88% (HR, 0.42; P = .0001): adding darolutamide to ADT and primary or salvage RT cut the risk of metastasis or death in very high-risk localized prostate canc
12. 01:37
    ESMO 2026 现场信号

    DASL-HiCaP: Darolutamide plus RTE in very high risk localized prostate cancer increases MFS (HR 0.42) and other secondary objectives. mFU: 2 years. A new SoC?: NGI and Biomarkers a
13. 00:45
    ESMO 2026 现场信号

    DASL-HiCaP #ESMO26
14. 00:26
    ESMO 2026 现场信号

    #ESMO26 Presidential Session presentation for DASL-HiCAP (ANZUP1801) @niazi_Dr7 @urotoday
15. 00:20
    ESMO 2026 现场信号

    DASL-HiCaP at #ESMO26, presented by @Niazi_Dr7: darolutamide + RT + 2 yrs ADT vs placebo in very high-risk prostate cancer (n=1,106)
16. 00:19
    ESMO 2026 现场信号

    New data from #ESMO2026: Results from DASL-HiCaP show that adding #darolutamide to ADT and radiotherapy improved metastasis-free survival in patients with very high-risk localized
17. 00:12
    ESMO 2026 现场信号

    @niazi_Dr7 with #DASL-HICAP trial ADT/XRT +/- darolutamide in high risk #prostatecancer. Darolutamide improves distant metastasis free survival. Similar AE profile. Highly powered
18. 00:08
    ESMO 2026 现场信号

    🚨📣📣 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️
19. 00:07
    ESMO 2026 现场信号

    DASL-HiCaP: ADT + RT +/- Darolutamide in very high risk localized prostate cancer or biochemically persistent/recurrent disease. Improvement in MFS. New evidence that ARPIs have a
20. 00:06
    ESMO 2026 现场信号

    Compelling presentation by Tamim Niazi! DASL-HiCaP: adding darolutamide to ADT + RT improved MFS in very high-risk nonmetastatic prostate cancer (HR 0.42; 4-year MFS 95% vs 88%). I
21. 00:00
    ESMO 2026 现场信号

    #ESMO26: The benefits of systemic treatment intensification in very high-risk, localised and relapsed #ProstateCancer treated with radiotherapy were shown in the phase II DASL-HiCa
22. 00:00
    ESMO 2026 现场信号

    #ESMO26: DASL-HiCaP and a substudy of PROTEUS phase II trials show that adding an androgen receptor pathway inhibitor (#ARPI) reduced the risk of #metastasis-free survival in very

1. 21:45
   ESMO 2026 现场信号

   OncoAlert 4Sight Abstracts to be Presented at #ESMO26
2. 12:24
   ESMO 2026 现场信号

   ⚡️LBA4⚡️ DASL-HiCaP (ANZUP1801) Ph 3 RCT #ESMO26

1. 20:27
   ESMO 2026 现场信号

   🚨 ESMO 2026 | TOP 10 GU CANCER TRIALS TO WATCH! From perioperative immunotherapy and AR pathway intensification to HIF-2α inhibition and long-term survival updates, GU oncology is…
2. 19:42
   ESMO 2026 现场信号

   DASL-HiCaP tests darolutamide + ADT + RT in very-high-risk localised prostate cancer, with MFS as the primary endpoint. The result magnitude is still pending. Key question: will th…

1. 05:42
   ESMO 2026 现场信号

   1/ 🧵 My prostate cancer picks for #ESMO26 - a thread Presidential session: DASL-HiCaP (LBA4, Sun 25 Oct, 16:30): intensified AR-targeted therapy with RT in very high-risk localise…

当前热度 97·可比范围峰值 129（10月25日 11:00）·近 24 小时可比范围变化 -2%·当前参与者 26

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。